Adverum Biotechnologies

Acquired

Redefining sight for life.

Redwood City, United States · Founded 2012 · $182.5M raised

Employees
51–200
Founded
2012
Total Funding
$182.5M
Last Round
$127.5M Private EquityFeb 2024
Rounds
2

About

Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, with the goal of developing functional cures that restore vision and prevent blindness. Leveraging its proprietary intravitreal (IVT) platform, Adverum is developing ixoberogene soroparvovec (Ixo-vec), a one-time, single-administration gene therapy for wet age-related macular degeneration, delivered in physicians' offices to eliminate the need for frequent ocular injections. Adverum is now a wholly-owned subsidiary of Eli Lilly and Company, following completion of Lilly's acquisition announced in October 2025.

Summary

Adverum Biotechnologies is a Biotech company based in Redwood City, United States, founded in 2012. It has raised $182.5M in total across 2 rounds, most recently a $127.5M Private Equity round in Feb 2024. Investors include TCGX, 5AM Ventures and Commodore Capital.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Private EquityPrivate EquityFeb 2024
$127.5M

Sign up to see all 2 rounds

Series B through Private Equity — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Adverum Biotechnologies on Indexed.vc
<a href="https://indexed.vc/companies/adverum-biotechnologies"><img src="https://indexed.vc/api/badge/company/adverum-biotechnologies" alt="Adverum Biotechnologies on Indexed.vc" width="260" height="76" /></a>